Fingerprint
Dive into the research topics of 'Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD–mutated, relapsed or refractory AML
Jorge E. Cortes, Martin S. Tallman, Gary J. Schiller, Denise Trone, Guy Gammon, Stuart L. Goldberg, Alexander E. Perl, Jean Pierre Marie, Giovanni Martinelli, Hagop M. Kantarjian, Mark J. Levis
Research output: Contribution to journal › Article › peer-review
121
Scopus
citations